Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since. Now, a bid to move ...
Novartis’ Kymriah is to receive fast reviews in the US and EU for a new use in a form of aggressive non-Hodgkin lymphoma, in a move that brings it into direct competition with Gilead's rival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback